Clinical Trials Logo

Alcohol Use Disorder (AUD) clinical trials

View clinical trials related to Alcohol Use Disorder (AUD).

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05992272 Recruiting - Stress Clinical Trials

Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer

ReCoDe
Start date: November 24, 2020
Phase:
Study type: Observational

Individuals with substance use disorders (SUD) have to cope with drug-related cues and contexts, which can affect instrumental drug seeking as shown with Pavlovian to instrumental transfer (PIT) paradigms in animals and humans. The investigators aimed to investigate the impact of acute and chronic stress on Pavlovian-to-instrumental transfer (PIT), how PIT it is associated with cognitive control abilities and whether such effects predict losing vs. regaining control in subjects with AUD. Moreover, the investigators aimed to develop a novel full transfer task that assesses both, general and specific PIT to investigate whether specific PIT differs between alcohol use disorder (AUD) and control subjects.

NCT ID: NCT05534568 Recruiting - Pregnancy Related Clinical Trials

The Oklahoma Parent-Child Assistance Program

Start date: November 15, 2022
Phase: N/A
Study type: Interventional

The Parent-Child Assistance Program (PCAP) helps mothers who have used alcohol, opioids, or other drugs during pregnancy and their children through the work of highly trained, closely supervised case managers. Case managers work closely with mothers over the course of three years, meeting the mothers in their own homes when possible, to help them to set goals and take advantage of available resources. The primary aims of PCAP include: (1) assisting mothers in obtaining substance use disorder (SUD) treatment and staying in recovery, (2) linking mothers to community resources that will help them build and maintain healthy, independent family lives for themselves and their children, and (3) preventing future drug and alcohol use during pregnancy. This study brings PCAP to Oklahoma (the state with the highest incarceration rate for women, where most enter the criminal justice system for drug charges) for the first time. This five-year project includes 200 women who will enroll in the study and be randomly assigned to the treatment (100 women) or control group (100 women). The intervention (i.e., PCAP services) will take place over a three-year period at two sites: Oklahoma City, Oklahoma and Tulsa, Oklahoma. This evaluation will measure participants' substance use, substance use disorder (SUD) treatment outcomes, and a host of other well-being outcomes-including but not limited to subsequent substance-exposed births, use of public assistance, education, use of family planning methods, and employment-to evaluate the effects of PCAP services. Among these, the investigators have identified four key outcomes: (1) the mother is on a reliable method of birth control, (2) abstinence for six months, (3) child custody (i.e., placement of children in foster care and/or with kinship providers), and (4) criminal justice involvement.

NCT ID: NCT05471154 Recruiting - Clinical trials for Alcohol Use Disorder (AUD)

Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders

NIBSSUD
Start date: September 22, 2022
Phase: N/A
Study type: Interventional

Every year, alcohol causes 3 million deaths worldwide. Even though a lot of treatments already exist, many of them are characterized by a high percentage of drop-out or relapse. Transcranial direct current stimulation (tDCS), a NIBS, is receiving increased attention as a possible new addiction treatment. However, little consensus exists in the concrete parameters (e.g. montage, current, intensity). Moreover, a lot of tDCS research focuses on subjective outcomes, like the report of craving, which are more prone to different biases and fluctuations. In this study, we aim to investigate the effect of HD-tDCS, a more focal stimulation variant, on AUDs. Using this intervention, stimulation can be restricted to one hemisphere, controlling for possible inhibition effects of the cathode. A between-subject design will be carried out, including patients with an AUD. Participants will receive 5 sessions of either real or sham right anodal HD-tDCS over the dorsolateral prefrontal cortex (dlPFC). Craving will be accounted for at baseline and after every stimulation session. Moreover, we will measure the activity of the brain in rest and during two inhibition tasks (Go/NoGo and cue reactivity task). This objective measure will be carried out both before (baseline) and at two time points after the stimulation, to measure effects on both the short and longer term. One month after the intervention, abstinence will be checked through a follow-up phone call. Through this study, we aim to describe positive effects of right dlPFC stimulation on craving, abstinence, and EEG measures.

NCT ID: NCT05414240 Recruiting - Alcoholism Clinical Trials

Ibudilast for Treating Alcohol Use Disorder

Ibudilast
Start date: January 14, 2023
Phase: Phase 2
Study type: Interventional

This is a research study involving 6 weeks of study medication, Ibudilast or a placebo (an inactive substance) and medical management counseling to reduce or stop drinking. Ibudilast is not approved by the U.S. FDA for clinical use in the United States, but it is has been used for many years in Japan for its anti-inflammatory effects. Its use in the treatment of alcohol dependence is experimental. By reducing inflammation, Ibudilast may help some people reduce or stop drinking. We have obtained an Investigational New Drug Application (IND) approval for this study from the FDA. Ibudilast has been used clinically for 20 years in Asia for treating bronchial asthma and, more recently, for post-stroke dizziness and ocular allergies and has been shown to be safe and well tolerated.

NCT ID: NCT05408247 Recruiting - Clinical trials for Alcohol Use Disorder (AUD)

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

NAC-AUD
Start date: February 16, 2023
Phase: Phase 4
Study type: Interventional

To explore the effectiveness of n-acetylcysteine in improving treatment outcomes for alcohol use disorder in a double-blind randomised placebo-controlled trial.

NCT ID: NCT05387148 Recruiting - Clinical trials for Alcohol Use Disorder (AUD)

The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence

Start date: June 2022
Phase: Phase 2
Study type: Interventional

The study will explore the psychophysiological and neurobiological and mechanisms of CBD in participants with alcohol use disorder

NCT ID: NCT05181891 Recruiting - Clinical trials for Alcohol Use Disorder (AUD)

Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking

PERRAS
Start date: July 11, 2022
Phase: Phase 2
Study type: Interventional

Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.

NCT ID: NCT05134857 Recruiting - Clinical trials for Alcohol Use Disorder (AUD)

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

Start date: January 7, 2022
Phase: Phase 2
Study type: Interventional

A phase II randomized, double-blind, placebo-controlled clinical trial (RCT) to evaluate the ability of zonisamide (ZON) to decrease alcohol use among treatment-seeking adults with an alcohol use disorder (AUD).

NCT ID: NCT05015881 Recruiting - Alcohol Drinking Clinical Trials

Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder

Start date: November 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this study is to learn more about how a nutritional supplement "ketone ester" (deltaG ®) has an effect on brain and heart function and on alcohol consumption in individuals with and without alcohol use disorder. The study will use Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) scans after a single dose of ketone ester or Placebo in 10 people with alcohol use disorder and 10 healthy control volunteers.

NCT ID: NCT04998916 Recruiting - Clinical trials for Alcohol Use Disorder

MPFC Theta Burst Stimulation as a Treatment Tool for Alcohol Use Disorder: Effects on Drinking and Incentive Salience

Start date: July 6, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to develop transcranial magnetic stimulation (TMS), specifically TMS at a frequency known as theta burst stimulation (TBS), to see how it affects the brain and changes the brain's response to alcohol-related pictures. TMS and TBS are stimulation techniques that use magnetic pulses to temporarily excite specific brain areas in awake people (without the need for surgery, anesthetic, or other invasive procedures). TBS, which is a form of TMS, will be applied over the medial prefrontal cortex, (MPFC), which has been shown to be involved with drinking patterns and alcohol consumption. This study will test whether TBS can be used as an alternative tool to reduce the desire to use alcohol and reducing the brain's response to alcohol-related pictures.